57.27

1.18% 0.67

After Hours: 57.00 -0.27 -0.47%

Bristol Myers Squibb Co (BMY)

Overview News Price History Option Chain Financials Why BMY Down? Discussions Forecast Stock Split Dividend History

Bristol Myers Squibb Co stock is traded at $57.27, with a volume of 9.51M. It is up +1.18% in the last 24 hours and up +0.56% over the past month. Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Previous Close:

$56.60

Open:

$57.03

24h Volume:

9.51M

Relative Volume:

0.83

Market Cap:

$116.95B

Revenue:

$48.48B

Net Income/Loss:

$7.27B

P/E Ratio:

16.08

EPS:

3.5626

Net Cash Flow:

$11.91B

1W Performance:

+0.16%

1M Performance:

+0.56%

6M Performance:

+9.82%

1Y Performance:

+19.71%

1-Day Range:

$56.79

$57.81

1-Week Range:

$54.20

$57.81

52-Week Range:

$42.52

$62.89

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name

Bristol Myers Squibb Co

Sector

Healthcare (1102)

Industry

Drug Manufacturers - General (20)

Phone

(609) 252-4621

Address

ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY

Employee

32,500

Twitter

@BMSNEWS

Next Earnings Date

2026-07-30

Latest SEC Filings

BMY's Discussions on Twitter

Compare BMY vs LLY, JNJ, ABBV, MRK, AZN

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMY Bristol Myers Squibb Co	57.27	115.58B	48.48B	7.27B	11.91B	3.5626
LLY Lilly Eli Co	1,131.42	1.00T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	232.77	549.25B	96.36B	21.04B	17.80B	8.6488
ABBV Abbvie Inc	227.23	397.42B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	120.79	297.02B	65.51B	8.93B	14.12B	3.5532
AZN Astrazeneca Plc	185.95	281.95B	60.48B	10.40B	8.05B	3.3297

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-25-26	Initiated	RBC Capital Mkts	Sector Perform
Feb-20-26	Initiated	Barclays	Overweight
Jan-07-26	Upgrade	UBS	Neutral → Buy
Dec-15-25	Upgrade	BofA Securities	Neutral → Buy
Dec-12-25	Upgrade	Guggenheim	Neutral → Buy
Nov-13-25	Initiated	Scotiabank	Sector Perform
Aug-05-25	Downgrade	Daiwa Securities	Outperform → Neutral
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral
Apr-22-25	Initiated	Piper Sandler	Overweight
Dec-16-24	Upgrade	Jefferies	Hold → Buy
Dec-10-24	Resumed	BofA Securities	Neutral
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-13-24	Upgrade	Daiwa Securities	Neutral → Outperform
Nov-12-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-25-24	Downgrade	Citigroup	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform
Jul-29-24	Downgrade	Barclays	Overweight → Equal Weight
Mar-11-24	Downgrade	Societe Generale	Buy → Hold
Feb-06-24	Downgrade	Redburn Atlantic	Buy → Neutral
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-15-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-09-23	Initiated	Deutsche Bank	Hold
Nov-02-23	Downgrade	Daiwa Securities	Outperform → Neutral
Oct-27-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Oct-27-23	Upgrade	HSBC Securities	Reduce → Hold
Oct-27-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-20-23	Resumed	UBS	Neutral
Jul-14-23	Initiated	HSBC Securities	Reduce
Jul-10-23	Initiated	SVB Securities	Market Perform
Jun-28-23	Initiated	Daiwa Securities	Outperform
Mar-06-23	Initiated	Jefferies	Hold
Jan-17-23	Initiated	Cantor Fitzgerald	Overweight
Nov-18-22	Initiated	Credit Suisse	Neutral
Oct-10-22	Downgrade	Guggenheim	Buy → Neutral
Sep-14-22	Downgrade	Berenberg	Buy → Hold
Jun-03-22	Downgrade	Raymond James	Outperform → Mkt Perform
Apr-06-22	Resumed	Morgan Stanley	Underweight
Dec-17-21	Initiated	Goldman	Buy
Dec-09-21	Resumed	Wells Fargo	Equal Weight
Nov-19-21	Initiated	BMO Capital Markets	Outperform
Nov-01-21	Downgrade	Argus	Buy → Hold
Jul-27-21	Resumed	Truist	Buy
Apr-30-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-13-21	Upgrade	Truist	Hold → Buy
Nov-16-20	Upgrade	Societe Generale	Hold → Buy
Nov-10-20	Resumed	Bernstein	Mkt Perform
Nov-06-20	Downgrade	Gabelli & Co	Buy → Hold
Oct-19-20	Upgrade	Guggenheim	Neutral → Buy
Sep-29-20	Initiated	Berenberg	Buy
Jul-28-20	Initiated	Raymond James	Outperform
Apr-02-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-23-20	Downgrade	Societe Generale	Buy → Hold
Feb-27-20	Initiated	Barclays	Equal Weight
Jan-06-20	Resumed	Citigroup	Buy
Dec-13-19	Upgrade	Argus	Hold → Buy
Nov-22-19	Resumed	Morgan Stanley	Equal-Weight
Oct-17-19	Resumed	BofA/Merrill	Buy
Aug-14-19	Upgrade	Atlantic Equities	Neutral → Overweight
May-28-19	Initiated	Goldman	Buy
May-20-19	Downgrade	Argus	Buy → Hold
May-03-19	Upgrade	Barclays	Equal Weight → Overweight
May-03-19	Resumed	JP Morgan	Overweight
Jan-15-19	Upgrade	Societe Generale	Sell → Buy
Oct-22-18	Downgrade	Citigroup	Buy → Neutral

View All

Bristol Myers Squibb Co Stock (BMY) Latest News

Jun 05, 2026

Assessing Bristol Myers Squibb (BMY) Valuation After Fresh EU Opdivo Approval And New Phase 3 Oncology Data - simplywall.st

Jun 05, 2026

Form 11-KAnnual report of employee stock purchase, savings and similar plans - ADVFN

Jun 05, 2026

Jun 04, 2026